Advertisement
Advertisement
U.S. markets close in 4 hours 58 minutes
Advertisement
Advertisement
Advertisement
Advertisement

Ayala Pharmaceuticals, Inc. (AYLA)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
2.0000+0.1600 (+8.70%)
As of 10:55AM EDT. Market open.
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Gravestone (Bullish)

Gravestone (Bullish)

Previous Close1.8400
Open1.8400
Bid1.9500 x 800
Ask2.0400 x 1000
Day's Range1.8400 - 2.1100
52 Week Range1.7500 - 14.9500
Volume29,110
Avg. Volume31,229
Market Cap28.171M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-2.7960
Earnings DateAug 11, 2022 - Aug 15, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est14.88
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for AYLA

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Ayala Pharmaceuticals, Inc.
    Daily – Vickers Top Buyers & Sellers for 04/27/2022The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
    Rating
    Fair Value
    Economic Moat
    22 days agoArgus Research
View more
  • Zacks

    Ayala Pharmaceuticals, Inc. (AYLA) Reports Q1 Loss, Misses Revenue Estimates

    Ayala Pharmaceuticals, Inc. (AYLA) delivered earnings and revenue surprises of 7.04% and 57.99%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

  • GlobeNewswire

    Ayala Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Corporate Update

    Interim data from Part A of RINGSIDE study of AL102 expected mid-2022REHOVOT, Israel and WILMINGTON, Del., May 16, 2022 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (Nasdaq: AYLA), a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers, primarily in genetically defined patient populations, today announced first-quarter 2022 financial results and provided a corporate update. “We continued t

  • GlobeNewswire

    Ayala Pharmaceuticals Announces Poster Presentation on AL101 at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting

    REHOVOT, Israel and WILMINGTON, Del., April 27, 2022 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (Nasdaq: AYLA), a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers, primarily in genetically defined patient populations, today announced that it will present a poster featuring data on AL101 in adenoid cystic carcinoma (ACC) at the 2022 American Society of Clinical Oncology (ASCO) Annual

Advertisement
Advertisement